Stock Buybacks!™ and the Monetization of Stock-Based Compensation

The circular process of issuing new shares to employees and then buying those shares back with company money - MY money as a shareholder - is called 'sterilization'.

Sterilization has been around forever, and to a limited degree it's fine. Yes, management teams should get some reasonable level of stock-based compensation. Yes, it may make sense to use some of my cash to sterilize those shares and keep the share count from expanding. But don't tell me that the sterilization of newly issued shares is anything other than a direct compensation expense that I am paying for with MY money. Don't tell me that the sterilization of newly issued shares is somehow a "return" of cash to ME, because it's just not. The sterilization of newly issued shares is a direct transfer of my money to YOU, the recipient of those newly issued shares. Nothing more, nothing less.

I believe that there has been a sea change in markets over the past ten years in the size and scope of these sterilizing stock buybacks.

I believe that there has been a truly astronomical transfer of wealth - well more than a trillion dollars - over the past ten years from shareholders of publicly traded companies to managers of publicly traded companies. Not founders, not entrepreneurs, not risk-takers ... managers.

I believe that this sea change has been driven by the intentional trumpeting of three narratives by management teams, boards of directors and their rah-rah Wall Street/CNBC accomplices:

  • "Our Interests Are Aligned" to justify larger and larger amounts of stock-based comp,

  • "Non-GAAP is the Best Way to Understand This Company's Fundamentals" to justify downplaying stock-based comp and share dilution as a crucial issue for investors, and

  • "We're Returning Cash to Shareholders" to justify the sterilization of that stock-based comp with stock buybacks.

Here's how it works:


Want to continue reading this and the other 1,500+ essays you won't find anywhere else?




Already a subscriber? log in here

To learn more about Epsilon Theory and be notified when we release new content sign up here. You’ll receive an email every week and your information will never be shared with anyone else.

Comments

  1. BOOM Ben --Fantastic work! Reminds me of the work you did on the AMA.

    I would change only one word:

    Step 4: Wall Street/CNBC Renfields trumpet the sterilizing stock buyback as “returning cash to shareholders”, encouraging shareholders to not only ignore the transfer of their money to management, but to embrace it.

  2. Bravo! Adding Apple as an example of non-mendacity forces the reader to confront the cartoon version rather than hiding behind the uncritical popularity of the tool. I also think that the closing argument that even greater mendacity has been rewarded at a negative cost of capital seals the deal. I am sending this note to outside advisors of our endowment as required reading for their analysts who pick individual stocks on our behalf.

  3. Avatar for bhunt bhunt says:

    Thanks, Patrick! I’ll get you a PDF version of the note later today for easier distribution.

  4. The fact that companies automatically pay the IRS in cash upon RSU vesting is an interesting one and not something I had realized. It seems almost as if these companies are taking a short position in their own stock, because on the grant date they are effectively making a promise to buy back a fixed percentage (say 30%) on the vesting date. The higher the stock price goes, the bigger the liability becomes.

  5. My “favorite” is the “we are authorizing a buyback to offset dilution” canned justification… while at the same time reporting Non-GAAP to because “stock compensation is a non-cash figure”

  6. Avatar for rguinn rguinn says:

    Long the narrative, short the fact!

  7. I asked my father (32 yrs as an advisor) what percentage of Meta’s FCF was used on buybacks and how much said buybacks shrank the float. When I gave him the actual numbers his jaw dropped. Normal investors have no idea how much they’re being played by some of these companies.

  8. Fantastic observation that I had not considered.

  9. Avatar for bhunt bhunt says:

    Most institutional investors, too!

  10. Great Note! None of the companies in this note have a high gross leverage or net leverage ratio but many companies do from issuing mountains of debt to buy back shares during the post GFC financial repression era. Not only taking shareholder money via sterilization but leaving them with a levered-up more vulnerable investment too. Alas the institutional bond investors fell over themselves to buy these deals because they were “10 bps cheap to secondaries” .

Continue the discussion at the Epsilon Theory Forum

20 more replies

Participants

Avatar for bhunt Avatar for rguinn Avatar for chudson Avatar for 010101 Avatar for Em_Lofgren Avatar for jpclegg63 Avatar for lpusateri Avatar for Desperate_Yuppie Avatar for acoates Avatar for henrybriley Avatar for Ncoulter Avatar for Btaff Avatar for lbr Avatar for acozzette Avatar for lcsonka39 Avatar for palmer Avatar for KonaKane

The Latest From Epsilon Theory

DISCLOSURES

This commentary is being provided to you as general information only and should not be taken as investment advice. The opinions expressed in these materials represent the personal views of the author(s). It is not investment research or a research recommendation, as it does not constitute substantive research or analysis. Any action that you take as a result of information contained in this document is ultimately your responsibility. Epsilon Theory will not accept liability for any loss or damage, including without limitation to any loss of profit, which may arise directly or indirectly from use of or reliance on such information. Consult your investment advisor before making any investment decisions. It must be noted, that no one can accurately predict the future of the market with certainty or guarantee future investment performance. Past performance is not a guarantee of future results.

Statements in this communication are forward-looking statements. The forward-looking statements and other views expressed herein are as of the date of this publication. Actual future results or occurrences may differ significantly from those anticipated in any forward-looking statements, and there is no guarantee that any predictions will come to pass. The views expressed herein are subject to change at any time, due to numerous market and other factors. Epsilon Theory disclaims any obligation to update publicly or revise any forward-looking statements or views expressed herein. This information is neither an offer to sell nor a solicitation of any offer to buy any securities. This commentary has been prepared without regard to the individual financial circumstances and objectives of persons who receive it. Epsilon Theory recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial advisor. The appropriateness of a particular investment or strategy will depend on an investor’s individual circumstances and objectives.